A six-month randomized, double-blind, placebo-controlled trial at the University of Surrey reported improvements in endothelial function, arterial stiffness and systolic blood pressure in 61 healthy adults aged 40 and older taking a daily multi-ingredient longevity supplement. Flow-mediated dilation rose 2.9 percentage points versus placebo, carotid-femoral pulse wave velocity differed by 1.18 m/s, and systolic pressure fell 6.1 mmHg, while blood lipids remained unchanged. Vascular function and arterial compliance are among the more reliable intermediate markers of cardiovascular and all-cause mortality risk.
Key Points
- Flow-mediated dilation improved 2.9 percentage points versus placebo over six months
- Systolic blood pressure fell 6.1 mmHg; arterial stiffness decreased 1.18 m/s
- Cholesterol and blood lipids unchanged, indicating a non-lipid mechanism
Longevity Analysis
Arterial stiffness and endothelial responsiveness track biological rather than chronological age, and both respond to sustained intervention rather than short-term dosing — the six-month duration here is as informative as the effect sizes. The absence of lipid movement alongside clear changes in vessel dilation and pulse wave velocity points toward nitric oxide availability and vascular tone rather than lipid handling, a distinction that matters when interpreting which markers to follow. For practitioners, the measurements themselves are the actionable element: flow-mediated dilation and pulse wave velocity detect declining circulatory capacity years before conventional panels register anything, and the trial was small, single-site and industry-supplied, which places it at the hypothesis-generating end of the evidence spectrum.
Original published by LT Wire.